Chinese researchers identified tumor-specific MHC-II (tsMHC-II) expression as a novel biomarker predicting response to neoadjuvant immunotherapy in gastric cancer. Single-cell profiling revealed higher MHC-II expression in tumor cells from treatment-sensitive patients. Validated in prospective trials, tsMHC-II-positive patients achieved 36.67% pathological complete response rate versus low rates in unselected populations. This simple immunohistochemistry-based biomarker outperforms current PD-L1 assessment and could guide personalized therapy for gastric cancer patients.

 This article explores recent advances in liposomal nanotechnology for photodynamic therapy, showing how improved drug loading, targeting, and light-activated efficiency are enhancing cancer treatment outcomes.

Scientists at City of Hope^® and TGen (part of City of Hope) are the first to explain a major mechanism for why gaining excess weight increases your risk of cancer.  The study, published today in Cancer Research, a journal of the American Association for Cancer Research, reveals a major driving force behind how obesity increases cancer risk across multiple organs. The findings emphasize the importance of maintaining a healthy weight from early childhood and propose a potentially more accurate way than body mass index (BMI) to predict the increase in cancer risk associated with obesity.  

In aggressive lymphomas, inflammatory messengers reprogram the “conductors” of the immune system, causing lymph nodes structure to collapse. A team led by Simon Haas describes in “Nature Cancer” this process for the first time using single-cell and spatial analyses.